Targeted next-generation gene sequencing found that individuals with metastatic castration-resistant prostate cancer who didn't respond to PSMA-targeted radiotherapy had mutations in 37 DNA checkpoint signaling, damage recognition or damage repair genes, as well as 15 whole-gene deletions, according to a study in the Journal of Nuclear Medicine. "Once it can be confirmed that a large number of patients receiving PSMA-TAT are simultaneously harboring potentially druggable mutations in genes that are causal related to radio-sensitivity, then clinical evaluation (and hopefully one day routine application) of combination therapies with the potential of over-additive efficacy will become available," said researcher Dr. Clemens Kratochwil.
Gene mutations found in therapy-resistant prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.